-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $36

Benzinga·12/01/2025 14:21:45
Listen to the news
Truist Securities analyst Karina Rabayeva initiates coverage on Immunome (NASDAQ:IMNM) with a Buy rating and announces Price Target of $36.